Eli Lilly and Company (LLY) vs Novo Nordisk A/S (NVO)
A side-by-side comparison of Eli Lilly and Company and Novo Nordisk A/S across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
LLY
Eli Lilly and Company
$1,144.09HealthcareDelayed quote: Sep 16, 2026, 11:05 AM EDT
NVO
Novo Nordisk A/S
$42.02HealthcareDelayed quote: Sep 16, 2026, 11:05 AM EDT
Total return — LLY vs NVO
growth of $100 · dividends reinvested · last 10yLLY +1555.7% (+32.4%/yr)NVO +135.8% (+9.0%/yr)LLY compounded faster over this window
Log scale — wide-divergence pair
LLY NVO
LLY vs NVO: by the numbers
- •LLY is the larger company ($1.08T vs $186.59B market cap).
- •NVO trades at the lower trailing earnings multiple (10.35 vs 38.39 P/E), one valuation lens rather than an overall verdict.
- •NVO converts more revenue to profit (35.33% vs 33.53% net margin).
- •LLY grew revenue faster over the past five years (24.42% vs 19.76% CAGR).
- •NVO pays the higher dividend yield (4.17% vs 0.60%).
Metrics side by side
Valuation
| Metric | LLY | NVO |
|---|---|---|
| P/E ratio | 38.39 | 10.35 |
| Forward P/E | 31.44 | N/A |
| P/S ratio | 13.52 | 3.65 |
| P/B ratio | 31.80 | 5.53 |
| EV / EBITDA | 30.65 | 7.67 |
| FCF yield | 1.86% | 3.99% |
Profitability
| Metric | LLY | NVO |
|---|---|---|
| Gross margin | 84.01% | 80.64% |
| Operating margin | 43.92% | 43.10% |
| Net margin | 33.53% | 35.33% |
| ROE | 78.84% | 53.50% |
| ROIC | 27.38% | 30.21% |
Dividends
| Metric | LLY | NVO |
|---|---|---|
| Dividend yield | 0.60% | 4.17% |
| Payout ratio | 22.45% | 44.27% |
Growth (annualized)
| Metric | LLY | NVO |
|---|---|---|
| Revenue CAGR (5Y) | 24.42% | 19.76% |
| EPS CAGR (5Y) | 28.88% | 19.59% |
| FCF CAGR (5Y) | 32.91% | -1.45% |
| Total return CAGR (5Y) | 37.25% | -0.65% |
Frequently asked
- Which has the lower trailing P/E, LLY or NVO?
- NVO has the lower trailing P/E: LLY trades at 38.39 and NVO at 10.35. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, LLY or NVO?
- Over the past five years, LLY grew revenue faster — LLY at a 24.42% CAGR versus NVO at 19.76%.
- Does LLY or NVO pay a bigger dividend?
- LLY yields 0.60% and NVO yields 4.17% based on trailing dividends and the latest price.
- Is LLY or NVO more profitable?
- NVO runs the higher net margin — LLY at 33.53% versus NVO at 35.33%.
- How have LLY and NVO total returns compared?
- Over the past 10 years, LLY delivered 32.48% and NVO delivered 9.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Eli Lilly P/E ratioNovo Nordisk A/S P/E ratioEli Lilly dividend yieldNovo Nordisk A/S dividend yieldEli Lilly ROENovo Nordisk A/S ROEEli Lilly operating marginNovo Nordisk A/S operating marginEli Lilly revenue growthNovo Nordisk A/S revenue growthEli Lilly free cash flowNovo Nordisk A/S free cash flow
Eli Lilly & Novo Nordisk A/S appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.